NCT06929338 - xDRIVE in Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Metastatic Colon AdenocarcinomaMetastatic Colon CancerMetastatic Rectal AdenocarcinomaMetastatic Rectal CarcinomaMetastatic Rectum Cancer

Interventions

DIAGNOSTIC_TEST

Functional precision medicine

The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices. Treatment will not be given as part of the study.